Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n ¼ 34) or CHOP (n ¼ 30). R-CHOP resulted in significantly higher overall response (OR) rate (94 vs 67%, P ¼ 0.0085) in the LPL patients and in the WM subgroup (91 vs 60%, P ¼ 0.0188). With a median observation time of 42 months, R-CHOP induced a significantly longer time to treatment failure (TTF) with a median of 63 months for R-CHOP vs 22 months in the CHOP arm in the LPL patients (P ¼ 0.0033) and in the WM subgroup (P ¼ 0.0241). There was no major difference of treatment-associated toxicity between both treatment groups. These data indicate that the addition of rituximab to front-line chemotherapy improves treatment outcome in patients with LPL or WM.
Introduction
In the current World Health Organization (WHO) classification, lymphoplasmacytic lymphoma (LPL), the former immunocytoma of the lymphoplasmacytic type in the Kiel classification, 1 is described as a rare indolent CD20-positive B-cell lymphoma, which is characterized by elements ranging from small lymphocytes, lymphoplasmacytoid forms to mature plasma cells. A subgroup of LPL patients represents with monoclonal immunoglobulin M (IgM) paraproteinemia and bone marrow involvement. These cases irrespective of the IgM serum concentration are defined as Waldenstroem's macroglobulinemia (WM). WM is considered to be a distinct clinicopathological entity and often presents with typical clinical symptoms, such as peripheral neuropathy or hyperviscosity syndrome, associated with IgM monoclonal gammopathy. [2] [3] [4] There are only few clinical studies reported in LPL: in a retrospective analysis treatment outcome was analyzed in 126 patients with immunocytoma according to the Kiel classification, including 24 patients with lymphoplasmacytic histology. In all, 13 of the 24 patients with lymphoplasmacytic histology were classified as WM. Patients were treated with various chemotherapy regimens including cyclophosphamide, vincristine and prednisone (CVP)-, doxorubicin-or fludarabine-containing regimens between 1972-1996, but only incomplete responses of short duration were documented. 5 In contrast to LPL, multiple phase II studies tested the efficacy of chemotherapy in WM: the standard front-line therapy in WM has been the use of alkylating agents or purine analogs, such as chlorambucil or fludarabine, respectively. However, the clinical activity of these compounds is limited: in a meta-analysis of 217 patients with WM treated with mostly chlorambucil, the overall response (OR) rate was 48% with a complete remission (CR) rate of 2%. 6 In a large nonrandomized study, fludarabine single-agent therapy induced a response in 36% of 182 patients with WM and a CR in 2% of cases. 7 In a randomized trial, fludarabine was significantly superior to a combination therapy of cyclophosphamide, doxorubicin and prednisone with a response duration of 19 vs 3 months in 92 patients with relapsed or primary refractory disease. 8 In a phase II study, analyzing 49 patients, the combination of fludarabine and cyclophosphamide achieved an OR of 77.6% and a median time to treatment failure (TTF) of 27 months. 9 All these data underline that conventional chemotherapy is effective in LPL and WM, but to a limited extent. CD20 is strongly expressed on most of the cells in LPL and WM forming a rationale to incorporate the anti-CD20 antibody rituximab into the therapy of this disease. Clinical trials on the efficacy of single-agent therapy in WM showed an OR up to 48%. 10 However, CR rates were low and the responses of short duration in the majority of patients. So far, there are no data from randomized phase III trials about the efficacy of rituximab/chemotherapy combinations in patients with LPL or WM, proven to be highly effective in follicular and other B-cell lymphomas. [11] [12] [13] On the basis of a multicenter randomized trial initiated by the German Low-Grade Lymphoma Study Group (GLSG), we now demonstrate that R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) significantly improves the response and TTF in previously untreated patients with LPL and WM compared with CHOP alone.
Patients and methods

Patients and entry criteria
This study was performed as a randomized, open-label multicenter phase III trial. It was started in 2000 and included patients at the age of 18 years and above with previously untreated advanced stage follicular lymphoma (FL), mantle cell lymphoma (MCL) and immunocytoma of the lymphoplasmacytic and lymphoplasmacytoid type according to the Kiel 1 classification. Randomization was stratified for histology, and the results of patients with FL and MCL have been reported previously.
11,14
Here, we report the results for patients with LPL according to the WHO classification corresponding to the immunocytoma of the lymphoplasmacytic type of the Kiel classification. Our analysis included patients with WM defined according to the criteria of the second Waldenstroem's workshop recommendations with the diagnosis of LPL, the presence of a monoclonal IgM on immunoelectrophoresis or immunofixation irrespective of IgM serum concentration and bone marrow involvement. 15 Eleven additional patients with lymphoplasmacytoid immunocytoma according to the Kiel classification, which is now considered to be a B-CLL variant in the WHO classification, were excluded from the analysis.
The histologic diagnosis was confirmed by central review at one of the six designated pathology reference centers.
Clinical entry criteria comprised stage III or IV disease and a requirement for therapeutic intervention as defined by the presence of B-symptoms and/or bulky disease (mediastinal mass 47.5 cm, or other nodal mass 45 cm in its greater diameter) and/or an impairment of normal hematopoesis (granulocytopenia o1.500/ml, Hb o10 g per 100 ml, thrombocytopenia o100 000/ml) and/or a rapidly progressive disorder, including symptomatic neuropathy or cryroglobulinemia.
The initial diagnostic work-up comprised the assessment of the extent of the disease including bone marrow biopsy, ultrasound examination of the abdomen and CT scans of chest and abdomen. Furthermore, the presence of monoclonal IgM gammopathy was tested by immunoelectrophoresis and/or immunofixation.
Randomization and treatment protocol
Patients were initially randomized between induction therapy with CHOP or R-CHOP. The CHOP combination comprised cyclophosphamide 750 mg/m 2 i.v., doxorubicin 50 mg/m 2 i.v., vincristine 1.4 mg/m 2 (max. 2.0 mg/day) i.v. on day 1 and prednisone 100 mg/m 2 orally on days 1-5. Treatment cycles were repeated every 3 weeks for a total of four to eight cycles. At signs of neuropathy, application of vincristine was stopped in the subsequent cycles. Patients who were randomized into the R-CHOP arm received a dose of 375 mg/m 2 /day rituximab on the day before the respective CHOP course.
After the first two cycles of initial cytoreduction, patients o60 years of age were offered a second randomization for treatment in remission to either myeloablative therapy followed by autologous stem cell transplantation or long-term interferon-a (IFN-a) maintenance. In the autologous stem cell transplantation (ASCT) arm, high-dose therapy consisted of intensification by the Dexa-BEAM regimen comprising dexamethason 3 Â 8 mg orally on days 1-10, BCNU 60 mg/m 2 /day on day 2, melphalan 20 mg/m 2 /day i.v. on day 3, etoposide 75 mg/m 2 /day i.v. on days 4-7 and cytosine arabinoside 2 Â 100 mg/m 2 every 12 h. i.v. on days 4-7 with subsequent stem cell harvest followed by myeloablative radiochemotherapy with total body irradiation (12 Gy) and cyclophosphamide 60 mg/kg/day for 2 days and stem cell retransfusion.
Patients responding to induction therapy started long-term IFN-a maintenance at a dose of three times 5 Â 10 6 U/week. All patients aged 60 years or above received IFN-a maintenance if they at least achieved a partial remission (PR) after initial four to six induction cycles of CHOP or R-CHOP. IFN-a maintenance therapy was given until lymphoma progression or the development of intolerable side effects.
The number of initial chemotherapy cycles depended on the response after four courses and planned postremission therapy. Induction therapy was stopped in patients achieving a CR after four cycles, when they were randomized for myeloablative therapy followed by an ASCT. In all other patients, six cycles of induction were planned. Patients assigned to IFN maintenance received two additional cycles of the initial cytoreductive regimen to balance the mobilization scheme (Dexa-BEAM) in the ASCT arm before starting long-term IFN-a maintenance. Thus, patients who achieved a PR after six cycles of initial therapy received a maximum of eight cycles of cytoreduction. Patients with progressive disease at any time during CHOP or R-CHOP therapy or stable disease after four to six cycles were taken off study.
Evaluation and response criteria
Response to therapy was assessed 3 weeks after every two cycles of CHOP or R-CHOP, respectively, and 4 weeks after the completion of last course. Response evaluation comprised a physical examination, the determination of blood counts, lactate dehydrogenase (LDH), IgM serum levels and an ultrasound of the abdomen and CT scans of previously involved areas. In patients with initial bone marrow involvement fulfilling otherwise the criteria of a CR, a bone marrow biopsy was performed.
For the follow-up, the aforementioned analyses were performed every 3 months except for CT scans of previously involved areas, which were repeated every 6 months.
Response was defined according to the International Working Group criteria and retrospectively at the time point of this analysis in patients fulfilling the criteria of WM according to the second Waldenstroem workshop. 16, 17 Hence, the CR comprised the elimination of all lymphoma manifestations for at least 4 weeks including the bone marrow and disappearance of the monoclonal protein in the serum, whereas PR was defined as a reduction of disease manifestations by at least 50% for more than 4 weeks including the IgM serum level tested by electrophoresis. In modification of the aforementioned criteria, the category of unconfirmed CR was not used. Instead, patients who fulfilled CR criteria, but in whom bone marrow biopsy was not evaluable, were counted as PR. The appearance of new nodal or extranodal manifestations, the enlargement of preexisting lymphoma manifestations or an increase of IgM serum levels by more than 25% were considered as progression.
Overall response (OR) was the achievement of CR or PR. Time to treatment failure was defined as the interval between the start of treatment and the documentation of resistance to initial therapy, progressive disease or death from any cause. The median observation time for TTF was calculated for patients without failure. Overall survival was defined as the interval between start of treatment and death from any cause. Analyses were performed on an intention-to-treat basis without censoring for patients refusing the scheduled treatment in remission or receiving other unplanned therapies.
The frequency and severity of side effects was recorded according to the WHO toxicity criteria.
Statistics
Time to treatment failure was defined as the primary statistical end point of this study for the indolent lymphomas included in this study (FL and LPL). The comparison of CHOP alone with R-CHOP was designed to test whether the addition of rituximab could reduce the risk for treatment failure in FL by 50% according to a proportional hazards assumption. On this basis, a one-sided triangular sequential test for log-rank analysis with a working significance level of 0.01 was applied. This procedure allowed for the detection of the assumed superiority of R-CHOP over CHOP alone with a probability of 95% in FL patients. The sequential procedure was designed to be equivalent in power and working significance level to a fixed sample test with 148 observations.
Lymphoplasmacytic lymphoma patients were included in the trial as the same clinical question was posed for this entity. However, because of the lower incidence of LPL, no formal sample size calculation was performed for this entity, and randomization was closed for LPL patients together with the FL patients.
After randomization was completed, further secondary analysis was performed of CR and overall response rate, duration of response, overall survival and safety using the Fisher exact test for binary responses and the log-rank test and univariate Cox regression analysis for time-censored observations. Efficacy comparisons were performed strictly according to the intention to treat.
Categorical baseline characteristics were compared with the Fisher's exact test, numerical baseline characteristics with the Mann-Whitney-U-test.
Multiple Cox regression for TTF was performed to assess interaction effects between treatment and histology and to adjust for prognostic factors. All interaction analyses first included the main effects together with the interaction term. In further adjusted analyses, the interaction term was only included if previously significant.
In the complete cohort of the trial, including patients with advanced stage LPL, FL and MCL, the interaction terms of histology (LPL vs FL vs MCL) with treatment (randomization to R-CHOP vs CHOP) were assessed in a model together with the main effects, histology and treatment. As no significant interaction was observed, the main effects of histology and treatment were then adjusted for prognostic factors. We used the following known prognostic factors of follicular lymphoma international prognostic index (FLIPI), 18 and mantle cell lymphoma international prognostic index (MIPI) 19 and for LPL patients' 4, 20 age, ECOG (Eastern Cooperative Oncology Group) performance status, LDH (quotient to upper limit of normal), hemoglobin, white blood cell count, platelet count, number of involved nodal areas and sex.
In the cohort of LPL patients, the effect of treatment was adjusted for the prognostic factors age, hemoglobin and platelet count in multiple Cox regression. Interaction effects were estimated for assignment to IFN maintenance and WM diagnosis, separately, and treatment effect subsequently adjusted for assignment to IFN maintenance or WM diagnosis, respectively.
All analyses were two-sided on a significance level of a ¼ 0.05.
Study conduct
The study was carried out in accordance with the modified Helsinki declaration. Before initiation, the study received approval by the responsible ethic committees. All patients gave written informed consent before participating in the trial.
Results
Characteristics of patients with LPL
Between June 2000 and August 2003, a total of 70 patients with LPL were enrolled into the trial. A total of 69 cases were randomized between R-CHOP and CHOP with 64 patients being evaluable for treatment outcome. The median age was 61 years ranging from 37 to 78 years. All patients had stage III/IV disease and were in need of therapy. In all, 48 of the 64 LPL cases fulfilled the criteria of WM with the histological diagnosis of LPL, bone marrow involvement and the presence of monoclonal serum IgM. In this WM patient group, the median age was also 61 years with a range from 37 to 78 years. The median hemoglobin, IgM and b 2 -microglobulin levels were 97 g/l, 34 g/l and 2.9 mg/l, respectively. Table 1 summarizes the main characteristics of patients with LPL, including the subgroup of patients with WM, indicating a balanced distribution between the two treatment arms. Figure 1 shows the patients' flow of the trial.
Treatment
A total of 34 patients with LPL were randomized into the R-CHOP arm, 30 patients received CHOP chemotherapy. Six patients of the R-CHOP arm and four patients of the CHOP arm were assigned to ASCT, the remaining 28 R-CHOP and 26 CHOP patients were assigned to IFN maintenance. In the group of patients classified as WM, 23 patients were treated with R-CHOP, 25 patients received CHOP. 52 of the patients with LPL (32 patients after R-CHOP and 20 patients after CHOP) achieved a CR or PR, and were therefore evaluable for postremission therapy. The majority of patients started IFN-a maintenance (20 after R-CHOP, 13 of these with WM, 10 after CHOP six with WM); in 14 patients (11 with WM), no further treatment was applied (seven after R-CHOP and seven after CHOP). Only eight patients finally received intensification followed by myeloablative radiochemotherapy and ASCT: Five (three with WM) patients after R-CHOP and three (all with WM) patients after CHOP. Thus, 84% of the responding patients in the R-CHOP arm compared with 85% in the CHOP arm received IFN-a maintenance or no further therapy, demonstrating a balanced distribution of postremission therapy in the two treatment groups (Table 2) .
Efficacy
The addition of rituximab to CHOP resulted in a significantly higher OR rate of 94 vs 67% in patients with LPL (95% CI, 80-99 vs 47-83%, P ¼ 0.0085). However, there was no significant difference in the CR rate between the two treatment arms (9%, 95% CI 2%-24 vs 7%, 95% CI 1-22%, P ¼ 1). Two patients experienced progressive disease after CHOP compared with none after R-CHOP (Table 3) In LPL patients, multiple regression analysis, including age, hemoglobin and platelet count, did not result in a smaller risk reduction (hazard ratio, 0.29, 0.13-0.64) comparing TTF according to randomization to R-CHOP or CHOP. Similar results as in the cohort of patients with LPL were observed in the subgroup of 48 evaluable WM patients: In the R-CHOP arm, a significantly higher OR rate of 91% (95% CI 72-99%) vs 60% (95% CI 39-79%) for CHOP alone was observed (P ¼ 0.0188), whereas the CR rates were not statistically different (9%, 95% CI 1-28% vs 4%, 95% CI 0-20%, P ¼ 0.60). R-CHOP led to a significantly longer TTF with a median 63 months for R-CHOP vs 22 months in the CHOP arm (P ¼ 0.0241; Figure 2b ) (probability of failure-free survival at 2 years are 0.47 (95% CI 0.26-0.65) and 0.78 (95% CI 0.54-0.90) for CHOP and R-CHOP, respectively).
No significant interaction term of clinical diagnosis of WM to the treatment effect was observed (P ¼ 1.0), and adjustment for WM diagnosis did not change the hazard ratio for TTF (0.38, 0.18-0.82).
When the analysis for TTF was restricted to patients assigned to IFN maintenance or no further therapy to exclude the possible impact of ASCT in the first remission on this parameter, differences between R-CHOP vs CHOP remained statistically significant in the LPL as well as WM group. No significant interaction term of assignment to IFN maintenance with the treatment effect was observed (P ¼ 0.33), and adjustment for assignment to IFN maintenance did not change the hazard ratio for TTF (0.35, 0.17-0.72). Abbreviations: ASCT, autologous stem cell transplantation; IFN, interferon; LPL, lymphoplasmacytic lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; t x , therapy; WM, Waldenstroem's macroglobulinemia. All five patients in the ASCT group who had achieved a PR after R-CHOP induction achieved a CR after ASCT, whereas all three patients in the CHOP arm remained in PR after ASCT. Three patients relapsed after ASCT, one in the CHOP group, after 18 months and two in the R-CHOP group, after 9 and 41 months. There was no death in remission so far.
LPL
At this time, the observation period is still relatively short for an assessment of overall survival. So far, 10 of the 64 LPL patients died, seven patients in the CHOP arm compared with three in the R-CHOP arm (P ¼ 0.11; Figure 4 ). In the subgroup of WM patients, 7 of 48 patients evaluable for overall survival died, five patients in the CHOP arm compared with two in the R-CHOP arm (P ¼ 0.28).
Side effects
Treatment-associated hematologic side effects comprised predominantly myelosuppression and granulocytopenia (Table 4) . Granulocytopenia of grades 3 and 4 occurred after 72% of R-CHOP-treated patients as compared with 57% of CHOPtreated patients (P ¼ 0.58). This difference was clinically of minor relevance, however, as grade 3/4 infections were encountered in 6% after R-CHOP compared with 13% after CHOP (P ¼ 0.58).
Nonhematological side effects consisted mainly of alopecia, nausea and vomiting, which occurred at similar frequencies after both regimens. The toxicity in the subgroup of patients classified as WM was similar to the whole cohort of LPL patients. 
Discussion
So far, conventional chemotherapy has shown only limited activity in patients with LPL or WM. In an effort to improve treatment outcome, Treon et al. 21 added rituximab to fludarabine in 43 evaluable patients with previously treated WM in a phase II study: immunochemotherapy induced a partial response in 35 patients with three patients achieving a CR. Response duration was encouraging with 36 of the 39 remaining in remission after a median follow-up of 17 months. However, toxicity was considerable with several patients experiencing grade III/IV neutropenia with subsequent delay of treatment or viral infections. 21 In another small series, five of nine evaluable patients with WM achieved a PR with rituximab/fludarabine/ cyclophosphamide. 22 In another phase II study, 72 patients with WM were treated front line with dexamethasone 20 mg i.v. followed by rituximab 375 mg/m 2 i.v. on day 1 and cyclophosphamide 100 mg/m 2 p.o. b.i.d. days 1-5 for a total of six courses repeated every 21 days: 83% of the patients responded (7% CR, 67% PR and 9% minor responses) with a 2-year progression-free survival of 67%. This regimen well tolerated with the exception of one patient, who died of interstitial pneumonia. 23 Taken together, these first experiences with rituximab/chemotherapy combinations in the treatment of WM suggested a high antilymphoma activity coupled with a tolerable toxicity profile. We now confirmed the efficacy of immunochemotherapy in a multicenter phase III study with significantly improved OR rates and prolongation of the TTF after R-CHOP induction compared with CHOP alone in previously untreated patients with LPL. The superiority of R-CHOP could be confirmed in the subgroup analysis of patients with WM, with an OR rate of 91 vs 60% and median TTF of 63 vs 22 months, although data have to be taken with caution because the sample size in our analyses was small. Importantly, in a situation of a noncurative disease occurring in patients mostly of advanced age, we did not see any additional toxicity in the R-CHOP arm compared wth CHOP alone.
These data of a multicenter prospective randomized study are remarkable in particular for patients with WM with an OR rate above 90% and a median TTF of over 5 years. Despite the encouraging results of R-CHOP in this trial, the CR rate was moderate with a CR in 2 of 25 patients, only. These data are in line with previous reports from phase II studies, demonstrating the difficulties to induce a CR in patients with LPL and WM even after rituximab/chemotherapy. 21, 23 One strategy to further improve the treatment outcome might be a dose-intensive consolidation, such as myeloablative radiochemotherapy, followed by an ASCT in the first remission. This concept was shown to improve the response quality in patients with advanced stage FL, increasing the proportion of patients in CR from 19.3% after CHOP or MCP (mitoxantrone, chlorambucil and prednisolone) to 52.1%. 24 In this series, mostly because of the age (460 years) of the patients at study entry, only eight patients received myeloablative radiochemotherapy followed by ASCT. Because of the very small size of this subgroup no definite conclusions can be drawn. However, in all patients, this treatment concept was feasible, in line with other reports on a small number of mostly pretreated patients with WM receiving high-dose therapy and autotransplants. 4, 25 Further studies will have to show whether dose-intensive approaches, such as ASCT, are indeed able to improve the long-term perspective of this patient group. Another attractive approach is the concept of maintenance. IFN maintenance as applied in this study was shown to be able to improve the progression-free survival in patients with FL compared with a watch and wait strategy. However, IFN maintenance is hampered by side effects forcing a substantial portion of patients to reduce dosages. [26] [27] [28] An alternative would be rituximab maintenance avoiding treatment-related toxicity associated with IFN application mostly in elderly patients with LPL or WM. But so far, there is no major experience with rituximab maintenance strategies after successful induction in patients with LPL or WM, previously shown to be highly efficient in patients with relapsed FL. 29, 30 Although our analysis is among very few randomized comparisons reported for LPL and WM, the data are based on a relatively small subgroup originating from a large randomized trial. However, in our trial, subgroup analysed according to the lymphoma entities were stabilized by stratified randomization. Furthermore, no substantial differences in baseline characteristics could be observed between the treatment arms in LPL patients. Analyses adjusted for known prognostic factors as potential confounders did not change the observed effects. In addition, the hazard ratios for TTF observed in LPL patients were similar to the results in the complete cohort of LPL, FL and MCL patients, as well as to the other subgroups, FL and MCL, and no significant interaction effect between histology and treatment could be detected. Thus, these data indicate that the results observed for LPL patients are qualitatively comparable to those already seen in FL and MCL patients, 11, 14 justifying the subgroup analyses for these separate lymphoma entities. 31 Taken together, our data indicate that in patients with LPL and WM, the addition of rituximab to a polychemotherapy, such as CHOP, can significantly improve OR rates as well as TTF compared with chemotherapy alone. These results establish R-chemotherapy as a highly attractive concept for the first-line treatment of these distinct lymphoma subtypes. However, further studies have to clarify whether other rituximab/ chemotherapy combinations, for example, rituximab in combination with purine analogues, such as fludarabine, will be superior to R-CHOP in these lymphoma entities.
